Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18999998 | 0.87 | CYP2C19 (0.45) | CYP2D6CYP2C19HPGDMMP1MMP8 | |
| SCHEMBL19010431 | 0.80 | CYP2D6 (0.36) | CYP2D6CYP2C19HPGDMMP1MMP8 | |
| SCHEMBL15218650 | 0.73 | CYP2D6 (0.38) | CYP2D6CYP2C19HPGDMMP1MMP8 | |
| SCHEMBL14577473 | 0.71 | CYP2D6 (0.46) | CYP2D6CYP2C19HPGDMMP1MMP8 | |
| SCHEMBL14577204 | 0.70 | CYP2D6 (0.50) | CYP2D6CYP2C19HPGDMMP1MMP8 | |
| SCHEMBL23489768 | 0.70 | CYP2D6 (0.42) | CYP2D6CYP2C19HPGDMMP1MMP8 | |
| SCHEMBL22951128 | 0.70 | KMT2A (0.42) | HPGDEPHX1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL5034969 | 0.68 | MCL1 (0.41) | MMP1MMP8LMNARAB9AKMT2A | |
| SCHEMBL19010433 | 0.67 | CYP2D6 (0.33) | CYP2D6CYP2C19HPGD | |
| SCHEMBL25128749 | 0.66 | CYP2D6 (0.45) | CYP2D6CYP2C19HPGDMMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115013-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP2D6 3082/4885CYP2C19 3278/4885HPGD 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.